About Stephen Bloch
Bloch is chief executive officer and co-founder of Allyx Therapeutics. Allyx develops oral medicines for Alzheimer’s and other neurodegenerative diseases. He also co-founded EvolveImmune Therapeutics and serves as its chief executive. EvolveImmune develops immune-based cancer treatments.
Bloch worked at Canaan as a general partner for almost two decades, helping launch and fund health care companies. He previously practiced medicine. He is also an Allyx director. He chairs EvolveImmune. He chairs Liquidia’s board and serves on the Dartmouth-Geisel Medical School Board of Advisors. BioCT named him its 2023 Entrepreneur of the Year. He earned an undergraduate degree at Dartmouth, a master’s at Harvard and a medical degree from Rochester. He completed radiology residency at Massachusetts General Hospital/Harvard and internal medicine residency at Lenox Hill Hospital/Cornell.
Experience
This experience comes from official bios, from Stephen Bloch's profile and from SEC filings. For roles taken from filings, the years are when the filings name Stephen Bloch in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Stephen Bloch works with at each company, as listed on that company's latest Form D.
